Interplay Between CCR7 and Notch1 Axes Promotes Stemness in MMTV-PyMT Mammary Cancer Cells

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2017 Feb 1

PMID 28137279

Citations 13

Authors

Sarah T Boyle

Krystyna A Gieniec

Carly E Gregor

Jessica W Faulkner

Shaun R McColl

Marina Kochetkova

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is the major cause of cancer-related mortality in women. It is thought that quiescent stem-like cells within solid tumors are responsible for cancer maintenance, progression and eventual metastasis. We recently reported that the chemokine receptor CCR7, a multi-functional regulator of breast cancer, maintains the stem-like cell population.

Methods: This study used a combination of molecular and cellular assays on primary mammary tumor cells from the MMTV-PyMT transgenic mouse with or without CCR7 to examine the signaling crosstalk between CCR7 and Notch pathways.

Results: We show for the first time that CCR7 functionally intersects with the Notch signaling pathway to regulate mammary cancer stem-like cells. In this cell subpopulation, CCR7 stimulation activated the Notch signaling pathway, and deletion of CCR7 significantly reduced the levels of activated cleaved Notch1. Moreover, blocking Notch activity prevented specific ligand-induced signaling of CCR7 and augmentation of mammary cancer stem-like cell function.

Conclusion: Crosstalk between CCR7 and Notch1 promotes stemness in mammary cancer cells and may ultimately potentiate mammary tumor progression. Therefore, dual targeting of both the CCR7 receptor and Notch1 signaling axes may be a potential therapeutic avenue to specifically inhibit the functions of breast cancer stem cells.

Citing Articles

Chemotherapy-induced cellular senescence promotes stemness of aggressive B-cell non-Hodgkin's lymphoma via CCR7/ARHGAP18/IKBα signaling activation.

Wang J, Tao Q, Huang K, Wang Y, Hu L, Ren A J Immunother Cancer. 2025; 13(1.

PMID: 39773566 PMC: 11749403. DOI: 10.1136/jitc-2024-009356.

Roles of transducin-like enhancer of split (TLE) family proteins in tumorigenesis and immune regulation.

Yu G, Chen Y, Hu Y, Zhou Y, Ding X, Zhou X Front Cell Dev Biol. 2022; 10:1010639.

PMID: 36438567 PMC: 9692235. DOI: 10.3389/fcell.2022.1010639.

Breast Cancer Stem Cells: Signaling Pathways, Cellular Interactions, and Therapeutic Implications.

Wang L, Jin Z, Master R, Maharjan C, Carelock M, Reccoppa T Cancers (Basel). 2022; 14(13).

PMID: 35805056 PMC: 9265870. DOI: 10.3390/cancers14133287.

C-C Chemokine Receptor 7 in Cancer.

Bill C, Allen C, Vines C Cells. 2022; 11(4).

PMID: 35203305 PMC: 8870371. DOI: 10.3390/cells11040656.

Expression of the Chemokine Receptor CCR7 in the Normal Adrenal Gland and Adrenal Tumors and Its Correlation with Clinical Outcome in Adrenocortical Carcinoma.

Fuss C, Other K, Heinze B, Landwehr L, Wiegering A, Kalogirou C Cancers (Basel). 2021; 13(22).

PMID: 34830848 PMC: 8616506. DOI: 10.3390/cancers13225693.

References

Sale S, Lafkas D, Artavanis-Tsakonas S . Notch2 genetic fate mapping reveals two previously unrecognized mammary epithelial lineages. Nat Cell Biol. 2013; 15(5):451-60. PMC: 4369920. DOI: 10.1038/ncb2725. View

Raju R, Gadakh S, Gopal P, George B, Advani J, Soman S . Differential ligand-signaling network of CCL19/CCL21-CCR7 system. Database (Oxford). 2015; 2015. PMC: 4620938. DOI: 10.1093/database/bav106. View

Dontu G, Jackson K, McNicholas E, Kawamura M, Abdallah W, Wicha M . Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004; 6(6):R605-15. PMC: 1064073. DOI: 10.1186/bcr920. View

Buonamici S, Trimarchi T, Ruocco M, Reavie L, Cathelin S, Mar B . CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature. 2009; 459(7249):1000-4. PMC: 3750496. DOI: 10.1038/nature08020. View

Kondratyev M, Kreso A, Hallett R, Girgis-Gabardo A, Barcelon M, Ilieva D . Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene. 2011; 31(1):93-103. DOI: 10.1038/onc.2011.212. View

Previs R, Coleman R, Harris A, Sood A . Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res. 2014; 21(5):955-61. PMC: 4333206. DOI: 10.1158/1078-0432.CCR-14-0809. View

Mirandola L, Apicella L, Colombo M, Yu Y, Berta D, Platonova N . Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1. Leukemia. 2013; 27(7):1558-66. DOI: 10.1038/leu.2013.27. View

Andre F, Cabioglu N, Assi H, Sabourin J, Delaloge S, Sahin A . Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol. 2006; 17(6):945-51. DOI: 10.1093/annonc/mdl053. View

Arial Zeng Y, Nusse R . Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell. 2010; 6(6):568-77. PMC: 2917779. DOI: 10.1016/j.stem.2010.03.020. View

10.

Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S . CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012; 72(11):2768-79. PMC: 3367125. DOI: 10.1158/0008-5472.CAN-11-3567. View

11.

Boyle S, Ingman W, Poltavets V, Faulkner J, Whitfield R, McColl S . The chemokine receptor CCR7 promotes mammary tumorigenesis through amplification of stem-like cells. Oncogene. 2015; 35(1):105-15. DOI: 10.1038/onc.2015.66. View

12.

Debeb B, Cohen E, Boley K, Freiter E, Li L, Robertson F . Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat. 2012; 134(2):495-510. PMC: 4545650. DOI: 10.1007/s10549-012-2075-8. View

13.

Mirandola L, Chiriva-Internati M, Montagna D, Locatelli F, Zecca M, Ranzani M . Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol. 2011; 226(5):713-22. DOI: 10.1002/path.3015. View

14.

Ling H, Sylvestre J, Jolicoeur P . Notch1-induced mammary tumor development is cyclin D1-dependent and correlates with expansion of pre-malignant multipotent duct-limited progenitors. Oncogene. 2010; 29(32):4543-54. DOI: 10.1038/onc.2010.186. View

15.

Artavanis-Tsakonas S, Rand M, Lake R . Notch signaling: cell fate control and signal integration in development. Science. 1999; 284(5415):770-6. DOI: 10.1126/science.284.5415.770. View

16.

Guo S, Liu M, Gonzalez-Perez R . Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta. 2011; 1815(2):197-213. PMC: 3060666. DOI: 10.1016/j.bbcan.2010.12.002. View

17.

Ma J, Lanza D, Guest I, Uk-Lim C, Glinskii A, Glinsky G . Characterization of mammary cancer stem cells in the MMTV-PyMT mouse model. Tumour Biol. 2012; 33(6):1983-96. DOI: 10.1007/s13277-012-0458-4. View

18.

Palacios-Arreola M, Nava-Castro K, Castro J, Garcia-Zepeda E, Carrero J, Morales-Montor J . The role of chemokines in breast cancer pathology and its possible use as therapeutic targets. J Immunol Res. 2014; 2014:849720. PMC: 4139084. DOI: 10.1155/2014/849720. View

19.

Visvader J, Lindeman G . Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012; 10(6):717-728. DOI: 10.1016/j.stem.2012.05.007. View

20.

Ayyanan A, Civenni G, Ciarloni L, Morel C, Mueller N, Lefort K . Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci U S A. 2006; 103(10):3799-804. PMC: 1450156. DOI: 10.1073/pnas.0600065103. View